Table 1 Clinical data of patients
| Â | Total | ZOL group n (%) | Control group n (%) |
|---|---|---|---|
Total | 86 | 40 | 46 |
Menopausal status | Â | Â | Â |
Premenopausal | 55 | 14 (35%) | 17 (37%) |
Postmenopausal | 31 | 26 (65%) | 29 (63%) |
Tumor size | Â | Â | Â |
pT1 | 51 | 26 (67%) | 25 (61%) |
pT2-3 | 29 | 13 (33%) | 16 (39%) |
Nodal status | Â | Â | Â |
Negative | 70 | 35 (90%) | 35 (85%) |
Positive | 10 | 4 (10%) | 6 (15%) |
Grading | Â | Â | Â |
I/II | 68 | 33 (87%) | 35 (88%) |
III | 10 | 5 (13%) | 5 (12%) |
ER status | Â | Â | Â |
Negative | 9 | 5 (14%) | 4 (12%) |
Positive | 60 | 30 (86%) | 30 (88%) |
PR status | Â | Â | Â |
Negative | 22 | 11 (31%) | 11 (32%) |
Positive | 47 | 24 (69%) | 23 (68%) |
HER2 status | Â | Â | Â |
Negative | 58 | 30 (86%) | 28 (85%) |
Positive | 10 | 5 (14%) | 5 (15%) |
DTC counts at diagnosis Median [range] | Â | 2 [1-6] | 2 [1-35] |